ArticleCurrent opinion in biomedical engineering2018
Translating Insights From Optogenetics To Therapies For Parkinson's Disease.
Article in Current opinion in biomedical engineering, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Roadmap for direct and indirect translation of optogenetics into discoveries and therapies for humans.Nature neuroscience · 2025Review
- Unraveling the Complexity of Parkinson's Disease: Insights into Pathogenesis and Precision Interventions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Quantifying harmony between direct and indirect pathways in the basal ganglia: healthy and Parkinsonian states.Cognitive neurodynamics · 2024Article
- Break-up and recovery of harmony between direct and indirect pathways in the basal ganglia: Huntington's disease and treatment.Cognitive neurodynamics · 2024Article
- Implication of regional selectivity of dopamine deficits in impaired suppressing of involuntary movements in Parkinson's disease.Neuroscience and biobehavioral reviews · 2024Review
- Neuronal and synaptic adaptations underlying the benefits of deep brain stimulation for Parkinson's disease.Translational neurodegeneration · 2023Review
- A micro-LED array based platform for spatio-temporal optogenetic control of various cardiac models.Scientific reports · 2023Article
- High frequency DBS-like optogenetic stimulation of nucleus accumbens dopamine D2 receptor-containing neurons attenuates cocaine reinstatement in male rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Article
- Editorial: Insights into the use of deep brain stimulation as a treatment for Parkinson's disease and related conditions.Frontiers in neuroscience · 2023Article
- A bibliometric profile of optogenetics: quantitative and qualitative analyses.Frontiers in neuroscience · 2023Article
- New Targets and New Technologies in the Treatment of Parkinson's Disease: A Narrative Review.International journal of environmental research and public health · 2022Review
- Deep Brain Stimulation for Addictive Disorders-Where Are We Now?Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Model-based optogenetic stimulation to regulate beta oscillations in Parkinsonian neural networks.Cognitive neurodynamics · 2022Article
- Current approaches to characterize micro- and macroscale circuit mechanisms of Parkinson's disease in rodent models.Experimental neurology · 2022Review
- Recent Advances in 3D Printing of Biomedical Sensing Devices.Advanced functional materials · 2022Article
- Applications and challenges of rhodopsin-based optogenetics in biomedicine.Frontiers in neuroscience · 2022Review
- Population-specific neuromodulation prolongs therapeutic benefits of deep brain stimulation.Science (New York, N.Y.) · 2021Article
- Soft subdermal implant capable of wireless battery charging and programmable controls for applications in optogenetics.Nature communications · 2021Article
- The Choice Between Advanced Therapies for Parkinson's Disease Patients: Why, What, and When?Journal of Parkinson's disease · 2020Review
- Neurons under genetic control: What are the next steps towards the treatment of movement disorders?Computational and structural biotechnology journal · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Movement disorders including Parkinson’s disease and dystonia are caused by neurological dysfunction, typically resulting from the loss of a neuronal input within a circuit. Neuromodulation, specifically deep brain stimulation (DBS), has proven to be a critical development in the treatment of movement disorders. Continuing efforts aim to improve DBS techniques, both in how they exert their effects and in the efficacy of the mechanism involved in eliciting those effects. While optogenetic stimulation is currently infeasible in human patients, opto-DBS research provides an indispensible avenue to understand the mechanisms of DBS therapeutic and adverse effects. We review the benefits of cell-type specific manipulations in understanding the root cause of movement disorders and how DBS might optimally combat those causes. We also explore new circuit-inspired applications of DBS suggested by thorough, high-throughput optogenetic techniques. Maximizing the efficacy and outcome of DBS requires a multi-tiered approach; research employing optogenetics provides the specificity and feasibility to uncover the mechanisms that will help realize these gains in patient care.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.